"Next up this morning we have Omeros Corporation (OMER) http://www.omeros.com/ currently trading in the $7.72 range on a 3-Month average daily trading volume of 74k+ shares. OMER has a 52-week high of $9.49 set on 10-08-09. OMER has a proprietary PharmacoSurgery platform that is designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. One of the drugs on the Co’s platform is OMS103HP, in Phase III clinical programs. Its PharmacoSurgery product candidates also include OMS302, which completed its Phase I/II clinical trial for use during ophthalmological procedures; and OMS201, which is in Phase I/II clinical trial for use during urological surgery. The company also engages in developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPARγ) agonists for the treatment and prevention of addiction to substances of abuse. Its pipeline of preclinical product development programs include MASP-2 program for developing proprietary mannan-binding lectin-associated serine protease-2 antibody therapies to treat disorders caused by complement-activated inflammation; PDE10 program for developing proprietary compounds to treat schizophrenia and other psychotic disorders; and PDE7 program for developing proprietary compounds to treat movement disorders. At its current price, OMER is a long-term (1 Yr) ‘Buy’ consideration for me."